Grimes & Company’s DexCom DXCM Stock Holding History

Grimes & Company’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-116,500	Closed	-$7.84M	–	470
2025 Q3	$7.84M	Sell	116,500 -17,554	-13%	-$1.39M	0.19%	92
2025 Q2	$11.7M	Sell	134,054 -881	-0.7%	-$69.1K	0.32%	69
2025 Q1	$9.21M	Buy	+134,935	New	+$11M	0.28%	84

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Grimes & Company's DXCM Position: Q4 2025 in Review

Grimes & Company sold out of DexCom (DXCM) in Q4 2025, closing a stake of 116,500 shares — an estimated $7.84M sold.

Grimes & Company first reported a position in DXCM in Q1 2025 and held it in 3 quarters. The position peaked at $11.7M in Q2 2025. 921 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Grimes & Company reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
Grimes & Company sold 116,500 DexCom shares in Q4 2025, an estimated $7.84M.
Grimes & Company first reported a position in DexCom in Q1 2025 and held it in 3 quarters.
Grimes & Company's DexCom position peaked at $11.7M in Q2 2025.
921 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Grimes & Company's 13F filing for Q4 2025, filed 3 Feb 2026.